Medical Advocates
HIV Drug Monitoring
  Phenotype Testing for HIV Drug
Resistance

General Reports
Efficacy
Phenotype/Genotype Comparison Studies
 Phenotype Comparison Studies
Brand Index




 
ARV Resist Monitoring Main New/Newsworthy  Home Page
Last Update:  January 21, 2012
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
General Reports
       

     Journal Papers, Abstracts, and Commentaries

  A randomized, prospective study of phenotype susceptibility testing versus
standard of care to manage antiretroviral therapy: CCTG 575.
Haubrich RH, Kemper CA, Hellmann NS, et al 
AIDS. 2005 Feb 18;19(3):295-302.
 Abstract		  
 
  POSTER
 Toward Optimal ART for HIV-2 Infection: Can Genotypic and Phenotypic Drug Resistance
Testing Help Guide Therapy in HIV-2?
 R Smith, S Ba, S Hawes,  et al
(17th CROI)
PDF Poster     Abstract
Efficacy
       

     Journal Papers, Abstracts, and Commentaries

 
Comparison of the rate and size of HIV-1 viral load blips with Roche COBAS TaqMan HIV-1 versions
1.0 and 2.0 and implications for patient management.
 Garrett NJ, Apea V, Nori A,  et al
J Clin Virol. 2012 Jan 17.|
 Abstract

Comparison of a Rule-Based Algorithm with a Phenotype-Based Algorithm for the Interpretation of HIV
Genotypes in Guiding Salvage Regimens in HIV-Infected Patients by a Randomized Clinical Trial: The
Mutations and Salvage Study.
Gianotti N, Mondino V, Rossi MC, et al
Clin Infect Dis. 2006 May 15;42(10):1470-80.
 Abstract

Development and evaluation of a phenotypic assay monitoring resistance formation
to protease inhibitors in HIV-1-infected patients.
 Gehringer H, Von der Helm K, Seelmeir S,  et al.
J Virol Methods 2003 May;109(2):143-52
 Abstract
 

  
     Conference Reports, Abstracts, and Posters
 
  17th CROI

 POSTER
 Novel High-throughput HIV-1 Protease-resistance Phenotypic Assay Using Cell-free
Protein Production System
T Masaoka T Sawasaki, S Matsunaga, et al  17th CROI
 PDF Poster          Abstract
 
POSTER
 Toward Optimal ART for HIV-2 Infection: Can Genotypic and Phenotypic Drug Resistance
Testing Help Guide Therapy in HIV-2?
 R Smith, S Ba, S Hawes,  et al
PDF Poster     Abstract

        1st European HIV Drug Resistance Workshop

 

PDF POSTER
 The VirtualPhenotype : A Quantitative Prediction Of HIV Drug Susceptibility From
Viral Genotype
L Bacheler, H van Marck, H Vermeiren, et al
 Poster
Phenotype/Genotype Comparison Studies
       

     Conference Reports, Abstracts, and Posters

POSTER
 Discrepant results between antiretroviral resistance mutations patterns by genotypic
analysis (Stanford HIV-SEQ program) and virtual phenotype (VircoNET)
 Pérez-Alvarez L, Carmona R, Muñoz M. et al 
(1st European HIV Drug Resistance Workshop)
PDF Poster

Phenotype Comparison  Studies
       

     Journal Papers, Abstracts, and Commentaries

 
Comparative Evaluation of the COBAS AmpliPrep/COBAS TaqMan HIV Type 1 Test (CAP/CTM) and
VERSANT HIV Type 1 RNA 3.0 Assay (bDNA) for Quantifying HIV Type 1 Viral Loads in China.
Xu S, Song A, Nie J, et al
AIDS Res Hum Retroviruses. 2008 Oct 18.
 Abstract
 
A Comparative Evaluation of the Automated Roche Taqman Realtime Quantitative HIV 1 RNA
PCR Assay with the Roche Amplicor V1.5 Conventional PCR Assay.
Oliver AR, Pereira SF, Clark DA.
 J Clin Microbiol. 2007 Sep 5;
 Abstract
 
Comparison of the precision and sensitivity of the Antivirogram and PhenoSense HIV drug
susceptibility assays.
Zhang J, Rhee SY, Taylor J, Shafer RW. 
 J Acquir Immune Defic Syndr. 2005 Apr 1;38(4):439-44.
Abstract

Real Versus Virtual Phenotype to Guide Treatment in Heavily Pretreated Patients:
48-Week Follow-Up of the Genotipo-Fenotipo di Resistenza (GenPheRex) Trial  
Mazzotta F, Caputo SL, Torti C, et al
J Acquir Immune Defic Syndr 2003 Mar 1;32(3):268-80
 Abstract

  
Cost/Benefit Studies
       
Select Phenotype Outcome Studies
       

     Journal Papers, Abstracts, and Commentaries  

  Comparative analysis of two commercial phenotypic assays for drug susceptibility
testing of human immunodeficiency virus type 1. 
Qari SH, Respess R, Weinstock H, et al.
J Clin Microbiol 2002 Jan;40(1):31-5
Abstract 		 

     Conference Reports, Abstracts, and Posters

        1st European HIV Drug Resistance Workshop

  POWERPOINT PRESENTATION
Quantitative assessment of resistance to fusion inhibitors in a replicative Phenotyping
assay.
V Brondani, F Hamy, T  Klimkait 
Presentation
Brand Index
       
Tibotec Virco (VirtualPhenotype , Antivirogram)

     Manufacturer's Information

VirtualPhenotype

    Journal Papers, Abstracts, and Commentaries  
 
 
Comparison of the Precision and Sensitivity of the Antivirogram and PhenoSense
HIV Drug Susceptibility Assays.
Zhang J, Rhee SY, Taylor J, Shafer RW.73
 J Acquir Immune Defic Syndr. 2005 Apr 1;38(4):439-444
 Abstract

Conflicting interpretations of the prevalence of mutations associated with drug resistance
in antiviral naive HIV-1 patients with acute and chronic infection.
 Re MC, Monari P, Bon I,  
Int J Antimicrob Agents. 2004 Feb;23(2):164-8.
 Abstract
 
PhenoSense

     Journal Papers, Abstracts, and Commentaries  
 
  Comparison of the Precision and Sensitivity of the Antivirogram and PhenoSense
HIV Drug Susceptibility Assays.
Zhang J, Rhee SY, Taylor J, Shafer RW.73
 J Acquir Immune Defic Syndr. 2005 Apr 1;38(4):439-444
 Abstract

ARV Resist Monitoring Main New/Newsworthy  Home Page

Genotype Testing for HIV Drug Resistance